The Council of the Hong Kong Laureate Forum Announced Deferment of Its Inaugural Hong Kong Laureate Forum to November 2022
18.5.2021 11:01:00 EEST | Business Wire | Press release
Given the prevailing situation of the COVID-19 pandemic, the progress of global and local vaccinations, as well as the global position on safe travel, the Board of the Council of the Hong Kong Laureate Forum Limited (the HKLF) has decided after careful consideration that the inaugural Hong Kong Laureate Forum (the Forum), originally scheduled to be held on 15-20 November 2021, would be deferred for one year to November 2022.
Importance of going face-to-face
The Board of the HKLF came to the view that the Forum should ideally be conducted in face-to-face mode given that the main aim of the Forum is to inspire young scientists by providing a platform of direct exchange amongst participating Shaw Laureates and young scientists. However, with the current situation of the pandemic, it is uncertain that safe and unrestricted international travel could be resumed in time for in-person meeting.
Professor Timothy W. TONG, BBS, JP, Chairman of the HKLF, is confident about delivering a successful inaugural Forum next year. He says, “As much as we would have liked to hold this world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit in November this year, it is not a suitable time to do so due to the pandemic. Our Forum aims to inspire young scientists from around the world and provide ample opportunities for exchanges between them and participating Shaw Laureates. We want to ensure that the inaugural Forum fulfils our objective of “Meeting of Inspirational Minds” and I am confident that the inaugural Forum in 2022 will be a great success”.
What happens next
The Secretariat of the HKLF will contact all participating Shaw Laureates and applicants individually as well as their working partners on the deferment. Upon fixing the date of the inaugural Forum next year, all stakeholders will then be notified.
Meanwhile, the Secretariat is planning a series of pre-Forum events targeting different segments of our audience. They would be held over a period of time, starting at end of Q3 this year. These include talk series by renowned scientists and exhibitions on scientific research, etc. Stay tuned to the HKLF website and announcement for details.
Background
The Forum is an annual scientific exchange event organised by the HKLF. It aspires to be a world-class academic exchange event to connect the current and next generations of leaders in scientific pursuit. The Forum also promotes understanding and interests of the young generation in Hong Kong and around the world in various disciplines in science and technology. The HKLF was launched in May 2019 and is fully sponsored by the Lee Shau Kee Foundation. The major partner of the HKLF is The Shaw Prize Foundation which organises the annual international award, The Shaw Prize.
Website: https://www.hklaureateforum.org
Facebook: https://www.facebook.com/HKLaureateForum
Twitter: https://www.twitter.com/HKLaureateForum
Weibo: https://www.weibo.com/hklaureateforum
LinkedIn: https://www.linkedin.com/company/hklaureateforum/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210518005468/en/
Contact information
Forum Programme and Participant Enquiry
Ms Koji Ho
programme@hklaureateforum.org
Tel: (852) 2905 6505
Media Enquiry
Mr Kelvin Chau
media@hklaureateforum.org
Tel: (852) 2905 6506
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two Single-Pill Triple Combination Lipid-Lowering Therapy Applications Validated in The European Union29.10.2026 13:27:00 EET | Press release
The European Medicines Agency (EMA) has validated two marketing authorization applications (MAA) from Daiichi Sankyo (TSE: 4568) for oral, single-pill triple-combination therapies. The applications seek approval for the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia to reduce low-density lipoprotein cholesterol (LDL-C) levels and cardiovascular (CV) risk. Despite the availability of effective therapies, treatment discontinuation remains a persistent challenge in lipid management.1,2 Across both primary and secondary prevention, a significant number of patients at high and very high CV risk do not reach their guideline-recommended LDL-C goals, often due to the complexity and pill burden of taking multiple medications.2 The applications cover two single-pill combinations of three established lipid-lowering agents: bempedoic acid with ezetimibe and atorvastatin, and bempedoic acid with ezetimibe and rosuvastatin.3 Multiple statin dose options of each of these
NIQ and Google Partner to Advance Agentic Commerce29.10.2026 12:45:00 EET | Press release
Today, NielsenIQ (NYSE: NIQ) and Google announced a broad collaboration to advance agentic commerce, aiming to bring NIQ’s global retail and product intelligence together with Google’s AI commerce ecosystem to improve product discovery and local availability. NIQ and Google are looking to complement Google's extensive Shopping Graph of more than 60 billion product listings with NIQ’s Commerce Intelligence. NIQ is also naming Google Cloud as a primary AI and cloud services provider, and plans to deploy Gemini for business across its global workforce. As AI evolves from helping consumers discover products to recommending and purchasing them, brands and retailers increasingly rely on trusted product information, real-world availability, and measurement. The partnership is designed to help make agentic commerce even more reliable and measurable, combining NIQ’s The Full View™ of consumer and retail intelligence with the scale and AI capabilities of Google Cloud and Gemini for business. The
TradeStation Europe Expands Options Capability, Including Extended-Hours Trading29.10.2026 12:43:00 EET | Press release
TradeStation Europe B.V. (“TradeStation Europe”), the recently licensed European brokerage subsidiary of TradeStation Group, Inc. (“TradeStation”), today announced a round of product updates, including extended-hours options trading, along with reduced options and equities pricing, new single-stock option spreads and expanded intraday trading to enhance the offering for retail and institutional traders across the Netherlands and the European Economic Area (EEA). Extended-hours options trading is now live. Clients can trade eligible equity options during a pre-market session from 7:30 a.m. to 9:25 a.m. ET and an extended curb session from 4:00 p.m. to 4:15 p.m. ET. The launch follows Cboe Global Markets, Inc.’s (Cboe: CBOE) introduction of extended trading hours for options on 24 individual stocks and five ETFs, expanding access to some of the most actively traded and liquid single-stock options outside of the regular U.S. trading session. The enhancement expands access beyond tradition
Chiesi Group appoints Paolo Paoletti to its Board of Directors29.10.2026 12:01:00 EET | Press release
Chiesi, the international research-focused biopharmaceutical group, today announced the appointment of Paolo Paoletti, M.D. to its Board of Directors, effective as of today. Paoletti is an internationally recognized pharmaceutical executive with more than 30 years of experience across research and development, corporate leadership and biotechnology innovation. Throughout his career, he has held senior leadership positions at Lilly, GlaxoSmithKline (GSK) and GammaDelta Therapeutics, contributing to the development and commercialization of innovative medicines across multiple therapeutic areas, particularly oncology. His appointment further strengthens the Board's scientific, innovation and global healthcare expertise as Chiesi continues to invest in research, international growth and long-term value creation. "On behalf of the Chiesi Board, I am delighted to welcome Paolo, whose commitment to scientific excellence and innovation reflects the same values that have guided Chiesi throughou
Icon Solutions Appoints Raquel Guillot as Southern Europe Sales Director to Drive Global Adoption of the Icon Payments Framework29.10.2026 11:30:00 EET | Press release
Icon Solutions – the UK fintech enabling banks globally to design and implement state-of-the-art payment systems – has appointed Raquel Guillot as Southern Europe Sales Director, to drive adoption of the Icon Payments Framework (IPF) across the region. Guillot brings around 20 years of experience spanning banking, analytics, fraud prevention, payments and core banking technology. She began her career at Citibank before moving into financial technology, holding roles at SAS, ACI Worldwide and other technology providers, including Thought Machine. IPF is the internationally proven payments development framework trusted by banks across the globe, including Citi, UBS, NatWest and BNP Paribas. It enables banks to transform their systems in an accelerated, structured and low-risk way, all on their own terms. Based in Madrid, Guillot will focus on expanding adoption of IPF among Tier 1 financial institutions across Southern Europe and Latin America, allowing them to deploy payment processing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom